Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar
Xbrane CEO Martin Åmark Highlights Potential For Xcimzane Rival To Cimzia
Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.
You may also be interested in...
With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.
Reports have named Intas as another possible buyer for Biogen’s biosimilars business, following earlier rumors that Samsung Bioepis could be interested in a deal. Generics Bulletin spoke to both Intas and Biogen for their reaction.
Rumors of another major biosimilars deal are spreading after Korean media reported that Samsung Bioepis could be considering a bid for Biogen’s biosimilars business.